Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response

References

• Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018;319:1802–19. doi:10.1001/jama.2018.3795.
   PubMed Web of Science ®Google Scholar
• Polaris Observatory C, Gamkrelidze I, Nguyen MH, Chen D-S, Van Damme P, Abbas Z, Abdulla M, Abou Rached A, Adda D, Aho I. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403. doi:10.1016/S2468-1253(18)30056-6.
   PubMed Web of Science ®Google Scholar
• Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, Chan HLY, Ng SC. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16(1):57–73. doi:10.1038/s41575-018-0055-0.
   PubMed Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, Zoulim F, Tacke F. European Association for the Study of the Liver. Electronic address eee, European association for the study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021.
   PubMed Web of Science ®Google Scholar
• Liaw Y-F, Sung JJ, Chow WC, Farrell G, Lee C-Z, Yuen H, Tanwandee T, Tao Q-M, Shue K, Keene ON, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–1531. doi:10.1056/NEJMoa033364.
   PubMed Web of Science ®Google Scholar
• Wong GL, Chan HL, Mak CW, Lee SKY, Ip ZMY, Lam ATH, Iu HWH, Leung JMS, Lai JWY, Lo AOS, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58(5):1537–1547. doi:10.1002/hep.26301.
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhou J, Wang L, Wu X, Chen Y, Piao H, Lu L, Jiang W, Xu Y, Feng B, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology. 2017;65(5):1438–1450. doi:10.1002/hep.29009.
   PubMed Web of Science ®Google Scholar
• Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases. Cell Mol Immunol. 2021;18(1):4–17. doi:10.1038/s41423-020-00592-6.
   PubMed Web of Science ®Google Scholar
• Liu C, Wang Y-L, Yang -Y-Y, Zhang N-P, Niu C, Shen X-Z, Wu J. Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. FASEB J. 2021;35(10):e21871. doi:10.1096/fj.202100939R.
   PubMed Web of Science ®Google Scholar
• Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375:2369–2379. doi:10.1056/NEJMra1600266.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Y, Zhang X, Liu J, Zhang Q, Zhao Y, Peng J, Feng Q, Dai J, Sun S, et al. Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients. Front Microbiol. 2017;8:2222. doi:10.3389/fmicb.2017.02222.
   PubMed Web of Science ®Google Scholar
• Wang X, Chen L, Wang H, Cai W, Xie Q. Modulation of bile acid profile by gut microbiota in chronic hepatitis B. J Cell Mol Med. 2020;24:2573–2581. doi:10.1111/jcmm.14951.
   PubMed Web of Science ®Google Scholar
• Yun Y, Chang Y, Kim HN, Ryu S, Kwon M-J, Cho Y, Kim H-L, Cheong H, Joo E-J. Alterations of the gut microbiome in chronic hepatitis B virus infection associated with alanine aminotransferase level. J Clin Med. 2019;8:173. doi:10.3390/jcm8020173.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, Wang Y, Zhu B, Li L. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54:562–572. doi:10.1002/hep.24423.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Xia P, Zhou X, Li X, Guo W, Zhu B, Zheng X, Wang B, Yang D, Wang J, et al. Hepatitis B virus infection alters gut microbiota composition in mice. Front Cell Infect Microbiol. 2019;9:377. doi:10.3389/fcimb.2019.00377.
   PubMed Web of Science ®Google Scholar
• Li X, Wu S, Du Y, Yang L, Li Y, Hong B. Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model. Int J Antimicrob Agents. 2020;56:106000. doi:10.1016/j.ijantimicag.2020.106000.
   PubMed Web of Science ®Google Scholar
• Chu H, Duan Y, Yang L, Schnabl B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut. 2019;68:359–370. doi:10.1136/gutjnl-2018-316307.
   PubMed Web of Science ®Google Scholar
• Sun X, Pan CQ, Xing H. Effect of microbiota metabolites on the progression of chronic hepatitis B virus infection. Hepatol Int. 2021;15(5):1053–1067. doi:10.1007/s12072-021-10230-6.
   PubMed Web of Science ®Google Scholar
• Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165:1332–1345. doi:10.1016/j.cell.2016.05.041.
   PubMed Web of Science ®Google Scholar
• Zhao M, Zhao L, Xiong X, He Y, Huang W, Liu Z, Ji L, Pan B, Guo X, Wang L, et al. TMAVA, a metabolite of intestinal microbes, is increased in plasma from patients with liver steatosis, inhibits gamma-butyrobetaine hydroxylase, and exacerbates fatty liver in mice. Gastroenterology. 2020;158:2266–2281 e27. doi:10.1053/j.gastro.2020.02.033.
   PubMed Web of Science ®Google Scholar
• Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15:111–128. doi:10.1038/nrgastro.2017.119.
   PubMed Web of Science ®Google Scholar
• Sun M, Wu W, Chen L, Yang W, Huang X, Ma C, Chen F, Xiao Y, Zhao Y, Ma C, et al. Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis. Nat Commun. 2018;9(1):3555. doi:10.1038/s41467-018-05901-2.
   PubMed Web of Science ®Google Scholar
• Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A. 2010;107:12204–12209. doi:10.1073/pnas.0909122107.
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. J Hepatol. 2016;64(1):S71–S83. doi:10.1016/j.jhep.2016.01.026.
   PubMedGoogle Scholar
• Lan P, Zhang C, Han Q, Zhang J, Tian Z. Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance. Hepatology. 2013;58:73–85. doi:10.1002/hep.26339.
   PubMed Web of Science ®Google Scholar
• Paquissi FC. Immunity and fibrogenesis: the role of Th17/IL-17 axis in HBV and HCV-induced chronic hepatitis and progression to cirrhosis. Front Immunol. 2017;8:1195. doi:10.3389/fimmu.2017.01195.
   PubMed Web of Science ®Google Scholar
• Ye Y, Xie X, Yu J, Zhou L, Xie H, Jiang G, Yu X, Zhang W, Wu J, Zheng S, et al. Involvement of Th17 and Th1 effector responses in patients with Hepatitis B. J Clin Immunol. 2010;30(4):546–555. doi:10.1007/s10875-010-9416-3.
   PubMed Web of Science ®Google Scholar
• Li J, Qiu S-J, She W-M, Wang F-P, Gao H, Li L, Tu C-T, Wang J-Y, Shen X-Z, Jiang W, et al. Significance of the balance between regulatory T (Treg) and T helper 17 (Th17) cells during hepatitis B virus related liver fibrosis. PLoS One. 2012;7(6):e39307. doi:10.1371/journal.pone.0039307.
   PubMed Web of Science ®Google Scholar
• Behary J, Amorim N, Jiang X-T, Raposo A, Gong L, McGovern E, Ibrahim R, Chu F, Stephens C, Jebeili H. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun. 2021;12(1):187. doi:10.1038/s41467-020-20422-7.
   PubMed Web of Science ®Google Scholar
• Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A. 2017;114(40):10713–10718. doi:10.1073/pnas.1711235114.
   PubMed Web of Science ®Google Scholar
• Wang S, Li J, Wu S, Cheng L, Shen Y, Ma W, She W, Yang C, Wang J, Jiang W, et al. Type 3 innate lymphoid cell: a new player in liver fibrosis progression. Clin Sci (Lond). 2018;132(24):2565–2582. doi:10.1042/CS20180482.
   PubMed Web of Science ®Google Scholar
• Wilmanski T, Rappaport N, Earls JC, Magis AT, Manor O, Lovejoy J, Omenn GS, Hood L, Gibbons SM, Price ND, et al. Blood metabolome predicts gut microbiome alpha-diversity in humans. Nat Biotechnol. 2019;37:1217–1228. doi:10.1038/s41587-019-0233-9.
   PubMed Web of Science ®Google Scholar
• Muthamil S, Balasubramaniam B, Balamurugan K. Synergistic effect of quinic acid derived from syzygium cumini and undecanoic acid against candida spp. Biofilm and Virulence Front Microbiol. 2018;9:2835.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim YG, Khadke SK, Lee J. Antibiofilm and antifungal activities of medium-chain fatty acids against Candida albicans via mimicking of the quorum-sensing molecule farnesol. Microb Biotechnol. 2021;14:1353–1366. doi:10.1111/1751-7915.13710.
   PubMed Web of Science ®Google Scholar
• Shi J, Zhou J, Ma H, Guo H, Ni Z, Duan J, Tao W, Qian D. An in vitro metabolomics approach to identify hepatotoxicity biomarkers in human L02 liver cells treated with pekinenal, a natural compound. Anal Bioanal Chem. 2016;408:1413–1424. doi:10.1007/s00216-015-9202-4.
   PubMed Web of Science ®Google Scholar
• Cantorna MT, Snyder L, Arora J. Vitamin A and vitamin D regulate the microbial complexity, barrier function, and the mucosal immune responses to ensure intestinal homeostasis. Crit Rev Biochem Mol Biol. 2019;54(2):184–192. doi:10.1080/10409238.2019.1611734.
   PubMed Web of Science ®Google Scholar
• Chan HL, Elkhashab M, Trinh H, Tak WY, Ma X, Chuang W-L, Kim YJ, Martins EB, Lin L, Dinh P, et al. Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. J Hepatol. 2015;63(5):1086–1092. doi:10.1016/j.jhep.2015.06.025.
   PubMed Web of Science ®Google Scholar
• Huan B, Kosovsky MJ, Siddiqui A. Retinoid X receptor alpha transactivates the hepatitis B virus enhancer 1 element by forming a heterodimeric complex with the peroxisome proliferator-activated receptor. J Virol. 1995;69(1):547–551. doi:10.1128/jvi.69.1.547-551.1995.
   PubMed Web of Science ®Google Scholar
• Huan B, Siddiqui A. Retinoid X receptor RXR alpha binds to and trans-activates the hepatitis B virus enhancer. Proc Natl Acad Sci U S A. 1992;89:9059–9063. doi:10.1073/pnas.89.19.9059.
   PubMed Web of Science ®Google Scholar
• Marion S, Studer N, Desharnais L, Menin L, Escrig S, Meibom A, Hapfelmeier S, Bernier-Latmani R. In vitro and in vivo characterization of Clostridium scindens bile acid transformations. Gut Microbes. 2019;10(4):481–503. doi:10.1080/19490976.2018.1549420.
   PubMed Web of Science ®Google Scholar
• Der Heiden C V, Wadman SK, De Bree PK, Wauters EAK. Increased urinary imidazolepropionic acid, n-acetylhistamine and other imidazole compounds in patients with intestinal disorders. Clinica Chimica Acta. 1972;39:201–214. doi:10.1016/0009-8981(72)90317-8.
   PubMed Web of Science ®Google Scholar
• Koh A, Molinaro A, Ståhlman M, Khan MT, Schmidt C, Mannerås-Holm L, Wu H, Carreras A, Jeong H, Olofsson LE, et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell. 2018;175(4):947–961.e17. doi:10.1016/j.cell.2018.09.055.
   PubMed Web of Science ®Google Scholar
• Molinaro A, Bel Lassen P, Henricsson M, Wu H, Adriouch S, Belda E, Chakaroun R, Nielsen T, Bergh P-O, Rouault C, et al. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nat Commun. 2020;11(1):5881. doi:10.1038/s41467-020-19589-w.
   PubMed Web of Science ®Google Scholar
• Li Z, Guan M, Lin Y, Cui X, Zhang Y, Zhao Z, Zhu J. Aberrant lipid metabolism in hepatocellular carcinoma revealed by liver lipidomics. Int J Mol Sci. pp.18. 2017. doi:10.3390/ijms19010018
   PubMed Web of Science ®Google Scholar
• Zeng Y, Chen S, Fu Y, Wu W, Chen T, Chen J, Yang B, Ou Q. Gut microbiota dysbiosis in patients with hepatitis B virus–induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. J Viral Hepat. 2019;27:143–155. doi:10.1111/jvh.13216.
   PubMed Web of Science ®Google Scholar
• Liu Q, Li F, Zhuang Y, Xu J, Wang J, Mao X, Zhang Y, Liu X. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma. Gut Pathog. 2019;11(1):1. doi:10.1186/s13099-018-0281-6.
   PubMedGoogle Scholar
• Luo L, Ramanathan R, Horlbogen L, Mathialagan S, Costales C, Vourvahis M, Holliman CL, Rodrigues AD. A multiplexed HILIC-MS/HRMS assay for the assessment of transporter inhibition biomarkers in phase I clinical trials: isobutyryl-carnitine as an organic cation transporter (OCT1) biomarker. Anal Chem. 2020;92(14):9745–9754. doi:10.1021/acs.analchem.0c01144.
   PubMed Web of Science ®Google Scholar
• Liu W, Crott JW, Lyu L, Pfalzer AC, Li J, Choi S-W, Yang Y, Mason JB, Liu Z. Diet- and genetically-induced obesity produces alterations in the microbiome, inflammation and Wnt pathway in the intestine of Apc +/1638N Mice: comparisons and contrasts. J Cancer. 2016;7(13):1780–1790. doi:10.7150/jca.15792.
   PubMed Web of Science ®Google Scholar
• Galipeau HJ, Caminero A, Turpin W, Bermudez-Brito M, Santiago A, Libertucci J, Constante M, et al. Raygoza Garay JA, Rueda G, Armstrong S, Novel fecal biomarkers that precede clinical diagnosis of ulcerative colitis. Gastroenterology. 2021;160(5):1532–1545. doi:10.1053/j.gastro.2020.12.004.
   PubMed Web of Science ®Google Scholar
• Duncan SH, Louis P, Flint HJ. Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. Appl Environ Microbiol. 2004;70(10):5810–5817. doi:10.1128/AEM.70.10.5810-5817.2004.
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Lordan C, Ross RP, Cotter PD. Gut microbes from the phylogenetically diverse genus Eubacterium and their various contributions to gut health. Gut Microbes. 2020;12:1802866. doi:10.1080/19490976.2020.1802866.
   PubMed Web of Science ®Google Scholar
• Liu X, Mao B, Gu J, Wu J, Cui S, Wang G, Zhao J, Zhang H, Chen W. Blautia —a new functional genus with potential probiotic properties? Gut Microbes. 2021;13:1–21. doi:10.1080/19490976.2021.1875796.
   Web of Science ®Google Scholar
• Liu Q, Li B, Li Y, Wei Y, Huang B, Liang J, You Z, Li Y, Qian Q, Wang R, et al. Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis. Gut. 2022;71(5):899–909. doi:10.1136/gutjnl-2020-323565.
   PubMed Web of Science ®Google Scholar
• Wellhoner F, Doscher N, Woelfl F, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Pieper DH, Cornberg M. Eradication of chronic HCV infection: improvement of dysbiosis only in patients without liver cirrhosis. Hepatology. 2021;74(1):72–82. doi:10.1002/hep.31700.
   PubMed Web of Science ®Google Scholar
• Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, Cong M, Iwaisako K, Liu X, Zhang M, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology. 2012;143(3):765–776 e3. doi:10.1053/j.gastro.2012.05.049.
   PubMed Web of Science ®Google Scholar
• Tan Z, Qian X, Jiang R, Liu Q, Wang Y, Chen C, Wang X, Ryffel B, Sun B. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunol. 2013;191:1835–1844. doi:10.4049/jimmunol.1203013.
   PubMed Web of Science ®Google Scholar
• Fabre T, Kared H, Friedman SL, Shoukry NH. IL-17A enhances the expression of profibrotic genes through upregulation of the TGF-beta receptor on hepatic stellate cells in a JNK-dependent manner. J Immunol. 2014;193(8):3925–3933. doi:10.4049/jimmunol.1400861.
   PubMed Web of Science ®Google Scholar
• Dragon S, Rahman MS, Yang J, Unruh H, Halayko AJ, Gounni AS. IL-17 enhances IL-1beta-mediated CXCL-8 release from human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1023–9. doi:10.1152/ajplung.00306.2006.
   PubMed Web of Science ®Google Scholar
• Griffin GK, Newton G, Tarrio ML, Bu D-X, Maganto-Garcia E, Azcutia V, Alcaide P, Grabie N, Luscinskas FW, Croce KJ, et al. IL-17 and TNF-alpha sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol. 2012;188(12):6287–6299. doi:10.4049/jimmunol.1200385.
   PubMed Web of Science ®Google Scholar
• Tsai SL, Sheen IS, Chien RN, Chu CM, Huang HC, Chuang YL, Lee TH, Liao SK, Lin CL, Kuo GC, et al. Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J Biomed Sci. 2003;10:120–135.
   PubMed Web of Science ®Google Scholar
• Penna A, Del Prete G, Cavalli A, Bertoletti A, D’Elios MM, Sorrentino R, D’Amato M, Boni C, Pilli M, Fiaccadori F, et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology. 1997;25(4):1022–1027. doi:10.1002/hep.510250438.
   PubMed Web of Science ®Google Scholar
• Li J, Jia M, Liu Y, She W, Li L, Wang J, Jiang W. Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B. Liver Int. 2015;35:834–845. doi:10.1111/liv.12589.
   PubMed Web of Science ®Google Scholar
• Chou HH, Chien WH, Wu LL, Cheng C-H, Chung C-H, Horng J-H, Ni Y-H, Tseng H-T, Wu D, Lu X, et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. Proc Natl Acad Sci U S A. 2015;112(7):2175–2180. doi:10.1073/pnas.1424775112.
   PubMed Web of Science ®Google Scholar
• Ren Y-D, Ye Z-S, Yang L-Z, Jin L-X, Wei W-J, Deng -Y-Y, Chen -X-X, Xiao C-X, Yu X-F, Xu H-Z, et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy. Hepatology. 2017;65(5):1765–1768. doi:10.1002/hep.29008.
   PubMed Web of Science ®Google Scholar
• Yang X-A, Lv F, Wang R, Chang Y, Zhao Y, Cui X, Li H, Yang S, Li S, Zhao X, et al. Potential role of intestinal microflora in disease progression among patients with different stages of Hepatitis B. Gut Pathog. 2020;12(1):50. doi:10.1186/s13099-020-00391-4.
   PubMed Web of Science ®Google Scholar
• Gilbert JA, Lynch SV. Community ecology as a framework for human microbiome research. Nat Med. 2019;25(6):884–889. doi:10.1038/s41591-019-0464-9.
   PubMed Web of Science ®Google Scholar